title: Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy.
abstract: The purpose of this report is to evaluate the efficacy and safety of spiramycin/cotrimoxazole in the mother-to-child transmission of Toxoplasma gondii infection. We retrospectively analysed 76 infants born to mothers with toxoplasmosis during pregnancy and estimated the risk of mother-to-child transmission considering the gestational age at the time of infection. Seventy-six mothers were given spiramycin, cotrimoxazole and folinic acid; only two babies (2.6%) were infected by Toxoplasma and none of them showed signs or symptoms of congenital infection or interference of sulphamid on tetrahydrofolate reductase (THFR) either at birth or during follow-up. Treatment did not need to be stopped in any mother because of adverse drug effects. Our results seem to encourage the use of spiramycin/cotrimoxazole in women with toxoplasmosis during pregnancy.
authors: Department of Pediatrics, Pediatric Infectious Diseases Unit, Catholic University of the Sacred Heart, L.go A. Gemelli, 8, 00168 Rome, Italy. pvalentini@rm.unicatt.it
authors: P
authors: P
authors: Valentini
authors: M L
authors: ML
authors: Annunziata
authors: D F
authors: DF
authors: Angelone
authors: L
authors: L
authors: Masini
authors: M
authors: M
authors: De Santis
authors: A
authors: A
authors: Testa
authors: R L
authors: RL
authors: Grillo
authors: D
authors: D
authors: Speziale
authors: O
authors: O
authors: Ranno
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000517:prevention & control*; D012189:Retrospective Studies; D015572:Spiramycin / Q000009:adverse effects / Q000627:therapeutic use*; D014122:Toxoplasma / Q000187:drug effects; D014123:Toxoplasmosis / Q000188:drug therapy* / Q000635:transmission*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D015572:Spiramycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002955:Leucovorin